Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis, Seminars in Liver Disease, vol.30, issue.01, pp.3-16, 2010. ,
DOI : 10.1055/s-0030-1247128
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, International Journal of Cancer, vol.8, issue.19, pp.2893-2917, 2008. ,
DOI : 10.1002/ijc.25516
Estimating the world cancer burden: Globocan 2000, International Journal of Cancer, vol.85, issue.2, pp.153-156, 2000. ,
DOI : 10.2105/AJPH.85.10.1356
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.1440/pdf
Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011. ,
DOI : 10.1097/00002030-199912240-00012
Hepatocellular Carcinoma, New England Journal of Medicine, vol.365, issue.12, pp.1118-1127, 2011. ,
DOI : 10.1056/NEJMra1001683
Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-175, 2008. ,
DOI : 10.1016/j.respe.2008.03.117
URL : https://hal.archives-ouvertes.fr/inserm-00338335
Primitive liver cancers: epidemiology and geographical study in France, European Journal of Gastroenterology & Hepatology, vol.21, issue.9, pp.984-989, 2009. ,
DOI : 10.1097/MEG.0b013e3283293783
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan, Lancet, vol.2, pp.1129-1133, 1981. ,
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006. ,
DOI : 10.1001/jama.295.1.65
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children, New England Journal of Medicine, vol.336, issue.26, pp.1855-1859, 1997. ,
DOI : 10.1056/NEJM199706263362602
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004. ,
DOI : 10.1053/j.gastro.2004.09.014
Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women, American Journal of Epidemiology, vol.155, issue.4, pp.323-331, 2002. ,
DOI : 10.1093/aje/155.4.323
Chronic Hepatitis C in Alcoholic Patients: Prevalence, Genotypes, and Correlation to Liver Disease, Scandinavian Journal of Gastroenterology, vol.16, issue.11, pp.1113-1118, 1995. ,
DOI : 10.1002/hep.1840160203
Non-alcoholic fatty liver disease, Journal of Gastroenterology and Hepatology, vol.7, pp.186-190, 2002. ,
DOI : 10.1053/jlts.2001.23011
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, vol.155, issue.Suppl. 1, pp.1972-1978, 2010. ,
DOI : 10.1093/aje/155.4.323
Two cases of non-alcoholic steatohepatitis with development of hepatocellular carcinoma without cirrhosis, Journal of Gastroenterology and Hepatology, vol.12, issue.12, pp.1865-1866, 2006. ,
DOI : 10.1007/s00535-003-1308-3
Smoking, Hepatitis B Virus Infection, and Development of Hepatocellular Carcinoma, JNCI Journal of the National Cancer Institute, vol.87, issue.9, pp.1642-1643, 2011. ,
DOI : 10.1038/sj.bjc.6600582
Coffee drinking and hepatocellular carcinoma: An update, Hepatology, vol.48, issue.4, pp.1317-1318, 2009. ,
DOI : 10.1002/hep.23272
URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.23272/pdf
Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.7, pp.2347-2353, 2012. ,
DOI : 10.1210/jc.2012-1267
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C, Gut, vol.54, issue.7, pp.1003-1008, 2005. ,
DOI : 10.1136/gut.2004.050302
Statin Use and the Risk of Liver Cancer: A Population-Based Case???Control Study, The American Journal of Gastroenterology, vol.100, issue.5, pp.894-898, 2011. ,
DOI : 10.1073/pnas.2237238100
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection, Journal of Clinical Oncology, vol.30, issue.6, pp.623-630, 2012. ,
DOI : 10.1200/JCO.2011.36.0917
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection, Journal of Clinical Oncology, vol.31, issue.12, pp.1514-1521, 2013. ,
DOI : 10.1200/JCO.2012.44.6831
Hepatocellular carcinoma, The Lancet, vol.379, issue.9822, pp.1245-1255, 2012. ,
DOI : 10.1016/S0140-6736(11)61347-0
URL : https://hal.archives-ouvertes.fr/hal-01134844
Resection of Hepatocellular Carcinoma Without Preoperative Tumor Biopsy, Annals of Surgery, vol.234, issue.2, pp.206-209, 2001. ,
DOI : 10.1097/00000658-200108000-00010
Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis, Alimentary Pharmacology & Therapeutics, vol.3, issue.9, pp.1187-1194, 2007. ,
DOI : 10.1016/0016-5085(85)90324-5
Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent, Journal of Clinical Ultrasound, vol.41, issue.6, pp.261-272, 2006. ,
DOI : 10.1148/radiology.208.2.9680590
A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis, Gastroenterology, vol.131, issue.6, pp.1758-1767, 2006. ,
DOI : 10.1053/j.gastro.2006.09.014
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome?, Cancer Treatment Reviews, vol.33, issue.5, pp.437-447, 2007. ,
DOI : 10.1016/j.ctrv.2007.04.001
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review, Journal of Hepatology, vol.53, issue.2, pp.348-356, 2010. ,
DOI : 10.1016/j.jhep.2010.02.035
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus???Related Cirrhosis, Clinical Gastroenterology and Hepatology, vol.8, issue.2, pp.192-199, 2010. ,
DOI : 10.1016/j.cgh.2009.10.026
Sustained virological response to interferon-?? is associated with improved outcome in HCV-related cirrhosis: A retrospective study, Hepatology, vol.130, issue.3, pp.579-587, 2007. ,
DOI : 10.7326/0003-4819-116-2-97
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon, New England Journal of Medicine, vol.359, issue.23, pp.2429-2441, 2008. ,
DOI : 10.1056/NEJMoa0707615
Combined ?? fetoprotein testing and ultrasonography as a screening test for primary liver cancer, Journal of Medical Screening, vol.6, issue.2, pp.108-110, 1999. ,
DOI : 10.1136/jms.6.2.108
URL : http://journals.sagepub.com/doi/pdf/10.1136/jms.6.2.108
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-338, 1999. ,
DOI : 10.1055/s-2007-1007122
I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score, Oncology, vol.91, issue.5-6, pp.373-381, 2011. ,
DOI : 10.1093/jnci/91.2.151
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials, Cancer, vol.247, issue.11, 2010. ,
DOI : 10.1001/jama.247.18.2543
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-7109, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1443
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5, Cancer Research, vol.66, issue.24, pp.11851-11858, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1377
Molecularly targeted therapy in hepatocellular carcinoma, Biochemical Pharmacology, vol.80, issue.5, pp.550-560, 2010. ,
DOI : 10.1016/j.bcp.2010.03.034
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update, Hepatology Research, vol.47, issue.suppl 4, pp.147-154, 2013. ,
DOI : 10.1016/j.ejca.2011.05.007
Advanced unresectable hepatocellular carcinoma, Current Opinion in Oncology, vol.25, issue.4, pp.409-416, 2013. ,
DOI : 10.1097/CCO.0b013e3283621074
Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008. ,
DOI : 10.1016/j.gcb.2007.11.001
Toxicity of sorafenib: clinical and molecular aspects, Expert Opinion on Drug Safety, vol.3, issue.2, pp.275-287, 2010. ,
DOI : 10.1158/1078-0432.CCR-06-0051
Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008. ,
DOI : 10.1056/NEJMoa0708857
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009. ,
DOI : 10.1016/S1470-2045(08)70285-7
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib, Alimentary Pharmacology & Therapeutics, vol.127, issue.8, pp.949-959, 2011. ,
DOI : 10.1053/j.gastro.2004.09.015
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis, Gastrointest Cancer Res, vol.4, pp.40-44, 2011. ,
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Alimentary Pharmacology & Therapeutics, vol.30, issue.10, pp.1193-1201, 2011. ,
DOI : 10.1055/s-0030-1247131
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice, Digestive and Liver Disease, vol.44, issue.9, pp.788-792, 2012. ,
DOI : 10.1016/j.dld.2012.04.001
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010. ,
DOI : 10.1055/s-0030-1247132
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation, Clinical Transplantation, vol.16, issue.4, 2013. ,
DOI : 10.1002/lt.22047
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis, Journal of Clinical Gastroenterology, vol.43, issue.5, pp.489-495, 2009. ,
DOI : 10.1097/MCG.0b013e31818ddfc6
First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study, International Journal of Clinical Practice, vol.115, issue.Suppl 4, pp.675-683, 2012. ,
DOI : 10.1002/cncr.24029
Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation, Japanese Journal of Clinical Oncology, vol.13, issue.3, pp.768-773, 2010. ,
DOI : 10.1002/lt.21043
Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma, Oncology, vol.4, issue.2, pp.119-125, 2012. ,
DOI : 10.1002/hep.20933
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma, European Journal of Cancer, vol.47, issue.14, pp.2117-2127, 2011. ,
DOI : 10.1016/j.ejca.2011.05.007
Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial, International Journal of Cancer, vol.28, issue.10, pp.2448-2458, 2013. ,
DOI : 10.1200/jco.2010.28.15_suppl.tps178
Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.29, issue.30, pp.3960-3967, 2011. ,
DOI : 10.1200/JCO.2011.37.1021
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, vol.23, issue.2, pp.205-213, 2011. ,
DOI : 10.1111/j.1365-2036.2006.02704.x
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma, Cancer Chemotherapy and Pharmacology, vol.7, issue.3, pp.773-780, 2012. ,
DOI : 10.1016/S1359-6349(09)72082-8
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma, JAMA, vol.304, issue.19, pp.2154-2160, 2010. ,
DOI : 10.1001/jama.2010.1672
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma, Journal of Hepatology, vol.53, issue.1, pp.126-131, 2010. ,
DOI : 10.1016/j.jhep.2010.01.035
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1027, 2005. ,
DOI : 10.1200/JCO.2005.06.081
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development., Proceedings of the National Academy of Sciences, vol.92, issue.8, pp.3566-3570, 1995. ,
DOI : 10.1073/pnas.92.8.3566
The role of neuropilins in cancer, Molecular Cancer Therapeutics, vol.5, issue.5, pp.1099-1107, 2006. ,
DOI : 10.1158/1535-7163.MCT-05-0538
VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-591, 2008. ,
DOI : 10.4161/cbt.6.8.4363
Tumor Angiogenesis, New England Journal of Medicine, vol.358, issue.19, pp.2039-2049, 2008. ,
DOI : 10.1056/NEJMra0706596
Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients, European Journal of Cancer, vol.36, issue.6, pp.748-753, 2000. ,
DOI : 10.1016/S0959-8049(00)00003-4
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, vol.55, pp.3964-3968, 1995. ,
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer, Clin. Cancer Res, vol.2, pp.1679-1684, 1996. ,
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma, Cancer, vol.948, issue.5, pp.858-863, 1996. ,
DOI : 10.1111/j.1349-7006.1994.tb02904.x
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis, European Journal of Cancer, vol.34, issue.9, pp.1439-1447, 1998. ,
DOI : 10.1016/S0959-8049(98)00069-0
Prognostic significance of angiogenesis in human pancreatic cancer, British Journal of Cancer, vol.79, issue.9-10, pp.1553-1563, 1999. ,
DOI : 10.1038/sj.bjc.6690248
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480, Clin. Cancer Res, vol.7, pp.1932-1936, 2001. ,
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer, Clin. Cancer Res, vol.9, pp.1253-1258, 2003. ,
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy, British Journal of Cancer, vol.3, issue.7, pp.772-778, 2002. ,
DOI : 10.1007/BF00666040
Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study, JNCI Journal of the National Cancer Institute, vol.348, issue.6301, pp.881-886, 1997. ,
DOI : 10.1038/348555a0
Differential expression of vascular endothelial growth factor???A isoforms at different stages of melanoma progression, Journal of the American College of Surgeons, vol.197, issue.3, pp.408-418, 2003. ,
DOI : 10.1016/S1072-7515(03)00388-0
Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization, Chinese Journal of Cancer Research, vol.24, issue.1, pp.36-43, 2012. ,
DOI : 10.1007/s11670-012-0036-8
Expression of hypoxia-inducible factor 1?? and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival, World Journal of Gastroenterology, vol.11, issue.11, pp.1705-1708, 2005. ,
DOI : 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F
Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1??, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma, Clinical Cancer Research, vol.17, issue.16, pp.5463-5472, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-3096
Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma, Clin. Cancer Res, vol.9, pp.5339-5345, 2003. ,
Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness, The American Journal of Gastroenterology, vol.21, issue.4, pp.914-921, 2008. ,
DOI : 10.1016/0006-291X(91)91276-I
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clinical Cancer Research, vol.18, issue.8, pp.2290-2300, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2175
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.26, issue.18, pp.2992-2998, 2008. ,
DOI : 10.1200/JCO.2007.15.9947
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.24, issue.12, pp.1898-1903, 2006. ,
DOI : 10.1200/JCO.2005.04.9130
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.27, issue.6, pp.843-850, 2009. ,
DOI : 10.1200/JCO.2008.18.3301
Targeted therapy of hepatocellular carcinoma: Present and future, Journal of Gastroenterology and Hepatology, vol.47, issue.18S, pp.862-872, 2012. ,
DOI : 10.1016/j.ejca.2011.04.027
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, The Lancet Oncology, vol.10, issue.8, pp.794-800, 2009. ,
DOI : 10.1016/S1470-2045(09)70171-8
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study, Journal of Clinical Oncology, vol.27, issue.18, pp.3027-3035, 2009. ,
DOI : 10.1200/JCO.2008.20.9908
Emerging Targeted Strategies in Advanced Hepatocellular Carcinoma, Seminars in Liver Disease, vol.33, issue.S 01, pp.11-19, 2013. ,
DOI : 10.1055/s-0033-1333632
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0033-1333632.pdf
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study, Journal of Clinical Oncology, vol.31, issue.28, 2013. ,
DOI : 10.1200/JCO.2012.47.3009
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study, Journal of Clinical Oncology, vol.26, issue.12, pp.2013-2019, 2008. ,
DOI : 10.1200/JCO.2007.14.9930
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells, Journal of Pharmacology and Experimental Therapeutics, vol.337, issue.1, pp.155-161, 2011. ,
DOI : 10.1124/jpet.110.175786
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients, Cancer Cell, vol.11, issue.1, pp.83-95, 2007. ,
DOI : 10.1016/j.ccr.2006.11.021
Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy, Clinical Cancer Research, vol.14, issue.20, pp.6371-6375, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-5287
URL : http://clincancerres.aacrjournals.org/content/clincanres/14/20/6371.full.pdf
Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008. ,
DOI : 10.1016/S0002-9440(10)64083-7
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, vol.8, issue.4, pp.299-309, 2005. ,
DOI : 10.1016/j.ccr.2005.09.005
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells, Journal of Hepatology, vol.57, issue.1, pp.108-115, 2012. ,
DOI : 10.1016/j.jhep.2012.02.019
Control of angiogenesis by the pericyte: Molecular mechanisms and significance, EXS, vol.79, pp.419-428, 1997. ,
DOI : 10.1007/978-3-0348-9006-9_18
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Annals of Oncology, vol.44, issue.1, 2012. ,
DOI : 10.1016/j.jhep.2005.10.013
Human Adipose Tissue Is a Source of Multipotent Stem Cells, Molecular Biology of the Cell, vol.13, issue.12, pp.4279-4295, 2002. ,
DOI : 10.1091/mbc.E02-02-0105
A Review of the Microcirculation of Adipose Tissue: Anatomic, Metabolic, and Angiogenic Perspectives, Microcirculation, vol.4, issue.2, pp.211-232, 1997. ,
DOI : 10.3109/10739689709146786
Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice, Circulation Research, vol.94, issue.12, pp.1579-1588, 2004. ,
DOI : 10.1161/01.RES.0000132745.76882.70
Adipose tissue mass can be regulated through the vasculature, Proceedings of the National Academy of Sciences, vol.294, issue.5542, pp.10730-10735, 2002. ,
DOI : 10.1126/science.1063889
Angiogenesis modulates adipogenesis and obesity, Journal of Clinical Investigation, vol.117, issue.9, pp.2362-2368, 2007. ,
DOI : 10.1172/JCI32239
URL : http://www.jci.org/articles/view/32239/files/pdf
Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells, Circulation, vol.109, issue.10, pp.1292-1298, 2004. ,
DOI : 10.1161/01.CIR.0000121425.42966.F1
Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue, Circulation Research, vol.100, issue.4, pp.47-57, 2007. ,
DOI : 10.1161/01.RES.0000259564.92792.93
Angiogenic factors are elevated in overweight and obese individuals, International Journal of Obesity, vol.27, issue.11, pp.1308-1314, 2005. ,
DOI : 10.1038/sj.ijo.0802408
Obesity is associated with increased levels of circulating hepatocyte growth factor, Journal of the American College of Cardiology, vol.41, issue.8, pp.1408-1413, 2003. ,
DOI : 10.1016/S0735-1097(03)00231-6
Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1500, issue.1, pp.88-96, 2000. ,
DOI : 10.1016/S0925-4439(99)00091-5
Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia, pp.518-526, 2002. ,
Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects, Diabetologia, vol.46, issue.11, pp.1483-1488, 2003. ,
DOI : 10.1007/s00125-003-1221-6
Waist circumference and abdominal adipose tissue distribution: influence of age and sex, The American Journal of Clinical Nutrition, vol.12, issue.6, pp.1330-1334, 2005. ,
DOI : 10.1038/oby.2004.60
Adipose tissue volume determination in males by computed tomography and 40K, Int J Obes, vol.12, pp.249-266, 1988. ,
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, The Lancet, vol.371, issue.9612, pp.569-578, 2008. ,
DOI : 10.1016/S0140-6736(08)60269-X
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study, BMJ, vol.335, issue.7630, p.1134, 2007. ,
DOI : 10.1136/bmj.39367.495995.AE
Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults, New England Journal of Medicine, vol.348, issue.17, pp.1625-1638, 2003. ,
DOI : 10.1056/NEJMoa021423
Can Obesity Explain the Racial Difference in Stage of Breast Cancer at Diagnosis between Black and White Women?, Journal of Women's Health & Gender-Based Medicine, vol.11, issue.6, pp.527-536, 2002. ,
DOI : 10.1089/152460902760277886
Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status, Breast Cancer Research and Treatment, vol.123, issue.5, pp.159-169, 2001. ,
DOI : 10.1093/oxfordjournals.aje.a114305
Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group, Journal of Clinical Oncology, vol.22, issue.3, pp.446-453, 2004. ,
DOI : 10.1200/JCO.2004.04.181
Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer, JNCI: Journal of the National Cancer Institute, vol.98, issue.22, pp.1647-1654, 2006. ,
DOI : 10.1200/JCO.2006.06.0863
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer, Gut, vol.59, issue.3, pp.341-347, 2010. ,
DOI : 10.1136/gut.2009.188946
URL : https://hal.archives-ouvertes.fr/inserm-00476649
Does Obesity Influence the Prognosis of Metastatic Renal Cell Carcinoma in Patients Treated with Vascular Endothelial Growth Factor-Targeted Therapy?, The Oncologist, vol.16, issue.11, pp.1565-1571, 2011. ,
DOI : 10.1634/theoncologist.2011-0213
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents, The Oncologist, vol.16, issue.1, pp.71-81, 2011. ,
DOI : 10.1634/theoncologist.2010-0227
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace, Journal of Hepatology, vol.56, issue.6, pp.1384-1391, 2012. ,
DOI : 10.1016/j.jhep.2011.10.027
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations, Clinical Science, vol.115, issue.5, pp.141-150, 2008. ,
DOI : 10.1042/CS20070402
Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis, Clinical Gastroenterology and Hepatology, vol.5, issue.8, pp.938-945, 2007. ,
DOI : 10.1016/j.cgh.2007.02.039
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?, Hepatology, vol.73, issue.1, pp.150-155, 2002. ,
DOI : 10.1002/1097-0142(19940101)73:1<42::AID-CNCR2820730109>3.0.CO;2-D
Obesity Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients, Clinical Gastroenterology and Hepatology, vol.6, issue.4, pp.459-464, 2008. ,
DOI : 10.1016/j.cgh.2008.02.012
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, vol.55, issue.Suppl. 2, pp.1181-1191, 2007. ,
DOI : 10.7326/0003-4819-140-5-200403020-00010
Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008. ,
DOI : 10.1056/NEJMoa0708857
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009. ,
DOI : 10.1016/S1470-2045(08)70285-7
Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis, Seminars in Liver Disease, vol.30, issue.01, pp.3-16, 2010. ,
DOI : 10.1055/s-0030-1247128
Genomics and Signaling Pathways in Hepatocellular Carcinoma, Seminars in Liver Disease, vol.27, issue.1, pp.55-76, 2007. ,
DOI : 10.1055/s-2006-960171
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-7109, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1443
Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells, Circulation, vol.109, issue.10, pp.1292-1298, 2004. ,
DOI : 10.1161/01.CIR.0000121425.42966.F1
Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue, Circulation Research, vol.100, issue.4, pp.47-57, 2007. ,
DOI : 10.1161/01.RES.0000259564.92792.93
Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects, Diabetologia, vol.46, issue.11, pp.1483-1488, 2003. ,
DOI : 10.1007/s00125-003-1221-6
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer, Gut, vol.59, issue.3, pp.341-347, 2010. ,
DOI : 10.1136/gut.2009.188946
URL : https://hal.archives-ouvertes.fr/inserm-00476649
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents, The Oncologist, vol.16, issue.1, pp.71-81, 2011. ,
DOI : 10.1634/theoncologist.2010-0227
Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1208-1236, 2005. ,
DOI : 10.1016/0016-5085(88)90436-2
Management of hepatocellular carcinoma: An update, Hepatology, vol.10, issue.Suppl 1, pp.1020-1022, 2011. ,
DOI : 10.1016/S1470-2045(08)70285-7
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma, JNCI Journal of the National Cancer Institute, vol.12, issue.4, pp.698-711, 2008. ,
DOI : 10.1038/nm1377
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma, Seminars in Liver Disease, vol.30, issue.01, pp.52-60, 2010. ,
DOI : 10.1055/s-0030-1247132
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
Abdominal Fat: Standardized Technique for Measurement at CT, Radiology, vol.211, issue.1, pp.283-286, 1999. ,
DOI : 10.1148/radiology.211.1.r99ap15283
Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-845, 1988. ,
DOI : 10.2307/2531595
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience, Digestive Diseases, vol.1, issue.6, pp.609-616, 2012. ,
DOI : 10.1159/000339016
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Alimentary Pharmacology & Therapeutics, vol.30, issue.10, pp.1193-1201, 2011. ,
DOI : 10.1055/s-0030-1247131
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice, Digestive and Liver Disease, vol.44, issue.9, pp.788-792, 2012. ,
DOI : 10.1016/j.dld.2012.04.001
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis, Annals of Oncology, vol.44, issue.1, 2012. ,
DOI : 10.1016/j.jhep.2005.10.013
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib, Alimentary Pharmacology & Therapeutics, vol.127, issue.8, pp.949-959, 2011. ,
DOI : 10.1053/j.gastro.2004.09.015
Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma, Oncology, vol.84, issue.1, pp.6-13, 2013. ,
DOI : 10.1159/000342425
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial, Journal of Hepatology, vol.57, issue.4, pp.821-829, 2012. ,
DOI : 10.1016/j.jhep.2012.06.014
Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008. ,
DOI : 10.1016/j.gcb.2007.11.001
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis, Gastrointest Cancer Res, vol.4, pp.40-44, 2011. ,
First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study, International Journal of Clinical Practice, vol.115, issue.Suppl 4, pp.675-683, 2012. ,
DOI : 10.1002/cncr.24029
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function, Cancer Chemotherapy and Pharmacology, vol.135, issue.5, pp.1285-1290, 2011. ,
DOI : 10.1007/s00432-008-0496-x
Angiogenesis modulates adipogenesis and obesity, Journal of Clinical Investigation, vol.117, issue.9, pp.2362-2368, 2007. ,
DOI : 10.1172/JCI32239
URL : http://www.jci.org/articles/view/32239/files/pdf
Angiogenic factors are elevated in overweight and obese individuals, International Journal of Obesity, vol.27, issue.11, pp.1308-1314, 2005. ,
DOI : 10.1038/sj.ijo.0802408
Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults, New England Journal of Medicine, vol.348, issue.17, pp.1625-1638, 2003. ,
DOI : 10.1056/NEJMoa021423
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH, Gut, vol.58, issue.6, pp.839-844, 2009. ,
DOI : 10.1136/gut.2008.164053
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, vol.82, issue.1, pp.1604-1611, 2011. ,
DOI : 10.3109/17453674.2011.555368
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma, Clinical Cancer Research, vol.18, issue.8, pp.2290-2300, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2175
Waist circumference and abdominal adipose tissue distribution: influence of age and sex, The American Journal of Clinical Nutrition, vol.12, issue.6, pp.1330-1334, 2005. ,
DOI : 10.1038/oby.2004.60
Adipose tissue volume determination in males by computed tomography and 40K, Int J Obes, vol.12, pp.249-266, 1988. ,
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2335-2342, 2004. ,
DOI : 10.1056/NEJMoa032691
Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk, Oncology, vol.75, issue.3-4, pp.215-223, 2008. ,
DOI : 10.1159/000163850
109 GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) SECOND INTERIM ANALYSIS: CLINICAL FINDINGS IN CHILD-PUGH B SCORE SUBGROUPS, Journal of Hepatology, vol.56, pp.48-49, 2012. ,
DOI : 10.1016/S0168-8278(12)60123-8
Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma, Journal of Clinical Gastroenterology, vol.47, issue.10, 2013. ,
DOI : 10.1097/MCG.0b013e318293a825
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma, PLoS ONE, vol.4, issue.5, p.37563, 2012. ,
DOI : 10.1371/journal.pone.0037563.t002
Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma, Oncology, vol.15, issue.2, pp.108-114, 2013. ,
DOI : 10.1634/theoncologist.2009-0143
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib, European Journal of Gastroenterology & Hepatology, vol.22, issue.9, pp.1106-1110, 2010. ,
DOI : 10.1097/MEG.0b013e3283386053